Isochromosome 7q – i(7q) – is seen in a wide variety of hematologic malignancies and solid tumors, often as a secondary change to a characteristic primary translocation. Despite its high frequency, nothing is known about the formation and the pathogenetic outcome of this abnormality. To address these issues, we performed a detailed fluorescence in situ hybridization (FISH) investigation of four acute lymphoblastic leukemias, one acute myeloid leukemia, and two myxoid liposarcomas with i(7q). Using FISH with bacterial artificial chromosomes (BACs) mapping between 7p12.2 and 7q11.2, the breakpoints (BPs) in all seven cases were shown to cluster to an approximately 340 kb segment at 7p11.2, covered by the overlapping BAC probes RP11-760D2 and RP11-10F11. Thus, the i(7q) should formally be designated idic(7) (p11.2). In one of the cases, FISH with fosmids could narrow down the BP further to an 80-kb sequence delineated by G248P81983A10 and G248P8793H7. No known genes are located in the 340-kb BP cluster region, indicating that the idic(7)(p11.2) does not result in a fusion or deregulation of genes in this segment. The pathogenetically important outcome is thus likely to be an altered gene expression because of copy number changes. The clustering of breakpoints might be due to frequent intrachromosomal duplicons in the BP region.

Barbouti A, Stankiewicz P, Nusbaum C, Cuomo C, Cook A, Höglund M, Johansson B, Hagemeijer A, et al: The breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats. Am J Hum Genet 74:1–10 (2004).
Berend SA, Shaffer LG, Bejjani BA: Pure trisomy 10p involving an isochromosome 10p. Clin Genet 55:367–371 (1999).
Beverstock GC, de Meijer PHEM, ten Bokkel Huinink D, Pruijt JFM, den Ottolander GJ, Wessels HW, Mollevanger P: A case of isodicentric 7p as sole abnormality in a patient with acute myeloid leukemia. Cancer Genet Cytogenet 89:132–135 (1996).
Bugge M, Brandt CA, Petersen MB: DNA studies of mono- and pseudodicentric isochromosomes 18q. Am J Med Genet A 127:230–233 (2004).
Dahlén A, Debiec-Rychter M, Pedeutour F, Domanski HA, Höglund M, Bauer HCF, Rydholm A, Sciot R, Mandahl N, Mertens F: Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer 103:616–623 (2003).
Dhandha S, Hogge WA, Surti U, McPherson E: Three cases of tetrasomy 9p. Am J Med Genet 113:375–380 (2002).
Fioretos T, Strömbeck B, Sandberg T, Johansson B, Billström R, Borg Å, Nilsson P-G, Van Den Berghe H, et al: Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood 94:225–232 (1999).
Gardner RJM, Sutherland GR: Chromosome Abnormalities and Genetic Counseling, 3rd ed (Oxford University Press, Oxford 2004).
ISCN (1995): An International System for Human Cytogenetic Nomenclature. Mitelman F (ed). (S. Karger, Basel 1995).
Jin Y, Jin C, Salemark L, Martins C, Wennerberg J, Mertens F: Centromere cleavage is a mechanism underlying isochromosome formation in skin and head and neck carcinomas. Chromosoma 109:476–481 (2000).
Johansson B, Axelsson P, Billström R, Strömbeck B, Arheden K, Olofsson T, Cervin A, Adriansson M, et al: Isodicentric 7p, idic(7)(q11.2), in acute myeloid leukemia associated with older age and favorable response to induction chemotherapy: a new clinical entity? Genes Chromosomes Cancer 30:261–266 (2001).
Jonveaux P, Daniel MT, Martel V, Maarek O, Berger R: Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T gamma/delta lymphoma. Leukemia 10:1453–1455 (1996).
Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D: Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 103:110–116 (1998).
Mandahl N, Mertens F, Åman P, Rydholm A, Brosjö O, Willén H, Mitelman F: Nonrandom secondary chromosome aberrations in liposarcomas with t(12;16). Int J Oncol 4:307–310 (1994).
Martins C, Jin Y, Jin C, Wennerberg J, Höglund M, Mertens F: Fluorescent in situ hybridisation (FISH) characterisation of pericentromeric breakpoints on chromosome 5 in head and neck squamous cell carcinomas. Eur J Cancer 35:498–501 (1999).
Mertens F, Johansson B, Mitelman F: Isochromosomes in neoplasia. Genes Chromosomes Cancer 10:221–230 (1994).
Mitelman F, Johansson B, Mertens F: Mitelman Database of Chromosome Aberrations in Cancer. (2005).
Pasquali F, Panarello C, Bernasconi P, Casalone R: The isochromosome (17q) in chronic myelocytic leukaemia: mechanism of origin, centromeric function and clonal evolution. Hum Genet 62:89–90 (1982).
Paulsson K, Mörse H, Fioretos T, Behrendtz M, Strömbeck B, Johansson B: Evidence for a single-step mechanism in the origin of hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer 44:113–122 (2005).
Pui C-H, Carroll AJ, Raimondi SC, Schell MJ, Head DR, Shuster JJ, Crist WM, Borowitz MJ, et al: Isochromosomes in childhood acute lymphoblastic leukemia: a collaborative study of 83 cases. Blood 79:2384–2391 (1992).
Savary JB, Vasseur F, Flactif M, Willatt L, Lefebvre J, Ferguson-Smith MA, Deminatti MM: Cytogenetic and molecular investigations of an abnormal Y chromosome: evidence for a pseudo-dicentric (Yq) isochromosome. Ann Genet 35:134–139. (1992).
Scheurlen WG, Schwabe GC, Seranski P, Joos S, Harbott J, Metzke S, Döhner H, Poustka A, et al: Mapping of the breakpoints on the short arm of chromosome 17 in neoplasms with an i(17q). Genes Chromosomes Cancer 25:230–240 (1999).
Tuzun E, Sharp AJ, Bailey JA, Kaul R, Morrison VA, Pertz LM, Haugen E, Hayden H, et al: Fine-scale structural variation of the human genome. Nat Genet 37:727–732 (2005).
Wolff DJ, Miller AP, Van Dyke DL, Schwartz S, Willard HF: Molecular definition of breakpoints associated with human Xq isochromosomes: implications for mechanisms of formation. Am J Hum Genet 58:154–160 (1996).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.